Tag: CABA-201

Cabaletta Bio’s IND application for CABA-201 to treat systemic lupus erythematosus has been approved by the US FDA.

The US Food and Drug Administration has approved the company’s investigational new drug (IND) application for CABA-201, a fully human CD19-CAR T cell investigational therapy that contains the 4-1BB protein, according to Cabaletta Bio, Inc., a clinical-stage biotechnology company focused…

Back to top

This will close in 0 seconds

Registration Form


This will close in 0 seconds